# Amy K. Mottl

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/amy-k-mottl/

## Facts

| Field | Value |
| --- | --- |
| Citations | 4,435 |
| Field | Chronic Kidney Disease and Diabetes |
| h-index | 32 |
| i10-index | 69 |
| Last Known Institution | University of North Carolina at Chapel Hill |
| OpenAlex ID | https://openalex.org/A5009128263 |
| ORCID iD | 0000-0002-4258-1726 |
| Works | 209 |

## Researcher papers

- [Association of Type 1 Diabetes vs Type 2 Diabetes Diagnosed During Childhood and Adolescence With Complications During Teenage Years and Young Adulthood](https://scholariq.org/papers/association-of-type-1-diabetes-vs-type-2-diabetes-diagnosed-during-childhood-and/)
- [Finerenone with Empagliflozin in Chronic Kidney Disease and Type 2 Diabetes](https://scholariq.org/papers/finerenone-with-empagliflozin-in-chronic-kidney-disease-and-type-2-diabetes/)
- [N-Acetylcysteine for the Prevention of Radiocontrast Induced Nephropathy](https://scholariq.org/papers/n-acetylcysteine-for-the-prevention-of-radiocontrast-induced-nephropathy/)
- [Results from part A of the multi-center, double-blind, randomized, placebo-controlled NefIgArd trial, which evaluated targeted-release formulation of budesonide for the treatment of primary immunoglobulin A nephropathy](https://scholariq.org/papers/results-from-part-a-of-the-multi-center-double-blind-randomized-placebo/)
- [Chronic kidney disease and intensive glycemic control increase cardiovascular risk in patients with type 2 diabetes](https://scholariq.org/papers/chronic-kidney-disease-and-intensive-glycemic-control-increase-cardiovascular/)
- [Design of the COmbinatioN effect of FInerenone anD EmpaglifloziN in participants with chronic kidney disease and type 2 diabetes using a UACR Endpoint study (CONFIDENCE)](https://scholariq.org/papers/design-of-the-combination-effect-of-finerenone-and-empagliflozin-in-participants/)
- [CureGN Study Rationale, Design, and Methods: Establishing a Large Prospective Observational Study of Glomerular Disease](https://scholariq.org/papers/curegn-study-rationale-design-and-methods-establishing-a-large-prospective/)
- [SGLT2 Inhibition for CKD and Cardiovascular Disease in Type 2 Diabetes: Report of a Scientific Workshop Sponsored by the National Kidney Foundation](https://scholariq.org/papers/sglt2-inhibition-for-ckd-and-cardiovascular-disease-in-type-2-diabetes-report-of-2/)
- [SGLT2 Inhibition for CKD and Cardiovascular Disease in Type 2 Diabetes: Report of a Scientific Workshop Sponsored by the National Kidney Foundation](https://scholariq.org/papers/sglt2-inhibition-for-ckd-and-cardiovascular-disease-in-type-2-diabetes-report-of/)
- [Impact of primary kidney disease on the effects of empagliflozin in patients with chronic kidney disease: secondary analyses of the EMPA-KIDNEY trial](https://scholariq.org/papers/impact-of-primary-kidney-disease-on-the-effects-of-empagliflozin-in-patients/)
- [Acute eGFR Changes and Their Mediation of Albuminuria Reduction with Empagliflozin and Finerenone](https://scholariq.org/papers/acute-egfr-changes-and-their-mediation-of-albuminuria-reduction-with/)

## Researcher topics

- [Chronic Kidney Disease and Diabetes](https://scholariq.org/topics/chronic-kidney-disease-and-diabetes/)
- [Renal Diseases and Glomerulopathies](https://scholariq.org/topics/renal-diseases-and-glomerulopathies/)
- [Diabetes Treatment and Management](https://scholariq.org/topics/diabetes-treatment-and-management/)
- [Diabetes Management and Research](https://scholariq.org/topics/diabetes-management-and-research/)
- [Diabetes and associated disorders](https://scholariq.org/topics/diabetes-and-associated-disorders/)

## Researcher university

- [University of North Carolina at Chapel Hill](https://scholariq.org/institutions/university-of-north-carolina-at-chapel-hill/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.